Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer
The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.
Colorectal Cancer
DRUG: capiri-sutent
Maximum Tolerated Dose, after every completed doselevel
determine the safety and toxicity profile using the CTCAE criteria., after every completed doselevel
The primary objective of this Phase 1 study is to identify the recommended dose of capiri and of sunitinib for combination therapy subsequent phase II trials.